By Stephen Nakrosis
Shares of Innoviva, Inc. were trading higher in Monday’s after-hours market following news the Food and Drug Administration’s Antimicrobial Drugs Advisory Committee unanimously recommended approval of sulbactam-durlobactam to treat certain adult pneumonia patients.
A new drug application for sulbactam-durlobactam to treat pneumonia patients is currently under priority review by the FDA, the company said.
At 5:54 p.m. EDT, the company’s stock was trading 7.3% higher at $12.90 per share. The stock finished the day’s regular session with a 1.47% loss at $12.02 per share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
Read the full article here
